Entera Bio Ltd. (ENTX) Stock Forecast
ENTX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $9.75 average of analyst targets
- Upside to target
- +263.8% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.07
- 52-week range
- $1.00 – $3.92
ENTX analyst ratings
5 analystsNumber of analysts at each rating.
ENTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ENTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.09 | −$0.05 | −$0.07 | +2.9% | 5 |
| Current fiscal year (2026) | −$0.40 | −$0.52 | −$0.25 | −$0.25 | −60.8% | 5 |
| Next fiscal year (2027) | −$0.42 | −$0.57 | −$0.35 | −$0.40 | −4.5% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ENTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
ENTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ENTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.08 | −$0.07 | −$0.07 | −15.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.34 | −$0.34 | −$0.34 | −$0.40 | −$0.40 | +18.2% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.57 | −$0.57 | −$0.57 | −$0.42 | −$0.42 | −26.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ENTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ENTX beat in 10 of 12.
What analysts expect from ENTX
5 analysts cover Entera Bio; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.75, 263.8% above the latest close of $2.68. Analysts expect earnings of −$0.40 per share for 2026, −60.8% from a year earlier. For 2027 the average estimate is −$0.42 per share. Entera Bio beat the EPS estimate in 10 of the last 12 quarters.
Related: ENTX income statement, ENTX key metrics, ENTX chart. See the ENTX stock overview for the latest quote and news.
ENTX forecast FAQ
What is Entera Bio's price target?
The average analyst price target for Entera Bio is $9.75, 263.8% above the latest close of $2.68.
Is Entera Bio a buy, hold or sell?
Of 5 analysts covering Entera Bio, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Entera Bio's EPS forecast?
Analysts forecast −$0.40 per share for 2026 (range −$0.52 to −$0.25); for 2027 the estimate is −$0.42.
When does Entera Bio report earnings?
Entera Bio is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes; the EPS estimate is $-0.07.
Does Entera Bio usually beat earnings estimates?
Entera Bio reported EPS at or above the analyst estimate in 10 of the last 12 quarters.